title: Normal statural growth in 2 infants on chronic peritoneal dialysis: anecdotal or whole management-related.
abstract: OBJECTIVE
  Growth retardation is usual in children on chronic peritoneal dialysis (CPD). Despite attention to many contributing factors (nutrition, dialysis dose, hemoglobin level, adynamic bone disease, hyperparathyroidism or rickets, growth hormone resistance, etc.), normal growth is rarely obtained in infants on CPD.
  
  
  METHODS
  We had the chance to observe normal growth over a 1 year period in 2 consecutively treated infants on CPD. Louise (renal hypodysplasia) required CPD at the age of 1 month: creatinine 430 micromol/l; oliguric, creatinine clearance lower than 5 ml/min/1.73 m2. Nutrition was achieved orally with human milk during the first 6 months of life. Tidal peritoneal dialysis allowed a high dialysis dose Kt/V urea 3.8/week and Kcreatinine 105 l/week/1.73 m2. Hemoglobin was maintained over 13 g/dl and low levels of vitamin D analogue were prescribed to avoid adynamic bone disease. At the age of 1 year her height was 75 cm. i.e. in the normal range for age. Madeline (renal hypodysplasia) commenced on CPD at the age of 6 weeks and managed similarly. Her height at 1 year of age was 74 cm.
  
  
  RESULTS
  In our 20 years of experience with children on dialysis, these 2 cases of normal statural growth for age at 1 year warrant discussion. As well as nutritional support, the new and recent therapeutic options in our team were: firstly, to avoid high doses of activated vitamin D to control PTH, as high doses are able to induce both a risk of adynamic bone disease and a direct bone cartilage toxicity: secondly, to maintain normal hemoglobin level; and thirdly, to deliver a high dialysis dose (urea, creatinine clearance) based on an individually adapted prescription.
  
  
  CONCLUSIONS
  We feel this management approach is necessary to achieve optimal statural growth in children on chronic peritoneal dialysis. But this management concept only based on clinical anecdotal observations needs further evaluation before its use in clinical guidelines.
authors.affiliation: Nephrology Dialysis Transplantation Children's Unit, University Hospital, Strasbourg, France. Michel.Fischbach@chru-strasbourg.fr
authors.forename: M
authors.initials: M
authors.lastname: Fischbach
authors.forename: J
authors.initials: J
authors.lastname: Terzic
authors.forename: S
authors.initials: S
authors.lastname: Menouer
authors.forename: E
authors.initials: E
authors.lastname: Provot
authors.forename: V
authors.initials: V
authors.lastname: Laugel
mesh_terms: D001827:Body Height / Q000502:physiology*; D001835:Body Weight / Q000502:physiology*; D005260:Female; D019382:Human Growth Hormone / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D007668:Kidney / Q000002:abnormalities; D007676:Kidney Failure, Chronic / Q000503:physiopathology*; D018529:Nutritional Support / Q000379:methods*; D010530:Peritoneal Dialysis / Q000379:methods*; D012016:Reference Values
chemical_list: D019382:Human Growth Hormone